Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?

Leuk Lymphoma. 2012 Sep;53(9):1824-7. doi: 10.3109/10428194.2012.661856. Epub 2012 Mar 13.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Cell Proliferation
  • Chromosomes, Human, Pair 8 / genetics
  • Chromosomes, Human, Pair 9 / genetics
  • Chronic Disease
  • Diagnosis, Differential
  • Erythroblasts / pathology*
  • Female
  • Humans
  • Hydroxyurea / therapeutic use
  • Hypereosinophilic Syndrome / diagnosis*
  • Hypereosinophilic Syndrome / drug therapy
  • Infant, Newborn
  • Interferon-alpha / therapeutic use
  • Oncogene Proteins, Fusion / genetics*
  • Pregnancy
  • Pregnancy Complications, Hematologic / diagnosis
  • Pregnancy Complications, Hematologic / drug therapy
  • Pregnancy Complications, Hematologic / genetics
  • Pregnancy Complications, Neoplastic / diagnosis
  • Pregnancy Complications, Neoplastic / drug therapy
  • Pregnancy Complications, Neoplastic / genetics
  • Translocation, Genetic*
  • Treatment Outcome
  • Young Adult

Substances

  • Antineoplastic Agents
  • Interferon-alpha
  • Oncogene Proteins, Fusion
  • PCM1-JAK2 fusion protein, human
  • Hydroxyurea